BeStock  
Stocks › Biotechnology › CRMD

CorMedix CRMD

US equityMarket cap rank #3659Biotechnology
$5.27 +$0.19 (+3.74%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $5.32 +0.95%
Open$4.96
Prev close$5.08
Day range$4.95 – $5.32
Volume3.61M
Market cap$419.16M
P/E (TTM)8.2
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership59.8%+2.00 pts vs. prior quarter
Institutions holding223-3 vs. prior quarter
Insider trades (recent)21 buys / 29 sellsNet selling
Short interest18.23% of floatDays to cover 8.4 · as of 30 Oct 2026
Short-sale volume share25.9%5-day average of daily volume

Short-sale volume as % of daily volume

15%21%28%34%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$817.4K (13 inflow days, 7 outflow days).

Net flow by order size, last 20 sessions

−$3.1MSuper+$2.3MBig+$228.6KMid−$408.6KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 29.7% of shares outstanding.

Largest holders

  • BlackRock8.28%
  • Deep Track Capital, LP8.05%
  • Shaibatalhamd Abdalkader5.93%
  • Vanguard Capital Management, LLC3.92%
  • American Century Investment Management3.49%
  • State Street Global Advisors3.38%
  • UBS Asset Management3.04%
  • Geode Capital Management, LLC2.45%

By investor type

  • Mutual Fund41.79%
  • VC/PE Fund8.05%
  • Individual/Insider7.42%
  • Hedge Fund4.95%
  • Public Company2.57%
  • Private Company1.40%
  • Government Pension Fund0.69%
  • Insurance Company0.25%

Reported short interest has fallen from 22.00% to 18.23% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
American Century Investment Management Mutual Fund 2026/Q3 +2,377,579 3.4%
UBS Asset Management Mutual Fund 2026/Q3 +375,295 3.0%
State Street Global Advisors Mutual Fund 2026/Q3 +320,623 3.3%
First Trust Advisors L.P. Mutual Fund 2026/Q3 +294,509 0.4%
Morgan Stanley Public Company 2026/Q3 +217,816 0.8%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +217,816 0.8%
JPMorgan Chase & Co. Public Company 2026/Q3 +194,451 0.3%
BlackRock Mutual Fund 2026/Q3 +129,043 8.3%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +173,182 0.2%
Bridgeway Capital Management, LLC Mutual Fund 2026/Q3 +551,664 0.9%
Armistice Capital LLC Hedge Fund 2026/Q3 +500,000 0.6%
BlackRock Mutual Fund 2026/Q3 +356,536 8.1%
Hudson River Trading LLC Private Company 2026/Q3 +333,113 0.8%
American Century Investment Management Mutual Fund 2026/Q3 +318,939 0.4%
Royce & Associates, LP Mutual Fund 2026/Q3 +288,830 2.8%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
17 Sep 2026 Janet Dillione Independent Director Derivative Exercise and Retained +48,909 – 87,382
28 Aug 2026 Elizabeth Masson-Hurlburt Executive VP and Chief Operating & Commercial Officer Sale to Issuer -8,076 $8.30 86,106
28 Aug 2026 Susan Blum EVP & Chief Financial Officer Sale to Issuer -8,424 $8.30 17,436
28 Aug 2026 Kaufman Zelnick EVP, Chief Legal and Compliance Officer & Corporate Secretary Sale to Issuer -8,424 $8.30 101,313
3 Feb 2026 Joseph Todisco CEO & Chairman of the Board of Directors Other Acquisition +77,156 – 373,664
3 Feb 2026 Elizabeth Masson-Hurlburt Executive VP and Chief Operating & Commercial Officer Other Acquisition +36,006 – 214,278
3 Feb 2026 Kaufman Zelnick EVP, Chief Legal and Compliance Officer & Corporate Secretary Other Acquisition +36,006 – –
25 Jan 2026 Myron Kaplan Lead Independent Director Other Acquisition +30,453 – 30,453
25 Jan 2026 Alan Dunton Independent Director Other Acquisition +30,453 – 30,453
25 Jan 2026 Janet Dillione Independent Director Other Acquisition +30,453 – 30,453
25 Jan 2026 Steven Lefkowitz Independent Director Other Acquisition +30,453 – 30,453
25 Jan 2026 Robert Stewart Independent Director Other Acquisition +30,453 – 30,453
25 Jan 2026 Gregory Duncan Independent Director Other Acquisition +30,453 – 30,453
22 Jan 2026 Joseph Todisco CEO & Chairman of the Board of Directors Sale to Issuer -27,306 $7.27 344,610
22 Jan 2026 Joseph Todisco CEO & Chairman of the Board of Directors Other Acquisition +225,900 – 352,983
22 Jan 2026 Elizabeth Masson-Hurlburt Executive VP and Chief Operating & Commercial Officer Sale to Issuer -10,778 $7.27 76,761
22 Jan 2026 Elizabeth Masson-Hurlburt Executive VP and Chief Operating & Commercial Officer Other Acquisition +93,010 – 165,772
22 Jan 2026 Susan Blum EVP & Chief Financial Officer Sale to Issuer -9,767 $7.27 8,438
22 Jan 2026 Susan Blum EVP & Chief Financial Officer Other Acquisition +72,820 – 124,301
22 Jan 2026 Kaufman Zelnick EVP, Chief Legal and Compliance Officer & Corporate Secretary Sale to Issuer -8,803 $7.27 –

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 14,205,973 18.2% 8.4
15 Oct 2026 14,665,697 18.8% 12.7
30 Sep 2026 15,422,728 19.8% 18.9
15 Sep 2026 16,202,272 20.8% 18.5
31 Aug 2026 16,032,112 20.6% 13.0
14 Aug 2026 17,149,908 22.0% 11.1

Discussion

No comments yet — be the first to weigh in on CRMD.

Sign in to join the discussion.

Scroll to Top